Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Significant increase in demand for NIB’s financing

During the first six months of 2022, the Bank has seen a significant increase in demand for its financing. NIB agreed a total of EUR 2,203 million in new loans and disbursed EUR 2,142 million, compared to EUR 664 million and EUR 1,266 million respectively in the same period in 2021.The new lending was distributed across different sectors and countries and include sustainability-linked loans and NIB’s first purchase of a bond eligible under the Minimum Requirement for its own funds and Eligible Liabilities (MREL) issued by a financial institution. “In these times, the need for the Nordic

Endomines reports new, high-grade drill results from the Pampalo gold mine

Endomines AB, stock exchange release 26th August 2022 at 09:00 CET   Endomines is pleased to report drill results from the underground core drilling program carried out in the spring/summer 2022 at the Pampalo Gold Mine in Finland. The drill program consisted of fifty tree (53) diamond drill holes for a total of 4 330 m. Drill holes were targeted to the area between the 815 and 875 mine levels, representing the next sixty (60) vertical meters below the current production area.   Highlighted drill results include:   · T-1753 intersected 8.2 meters at 13.1 g/t gold,

RLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2022

APRIL 1[st] – JUNE 30[th ](Previous year in brackets) · Net sales amounted to TSEK 397 (TSEK 244). · Earnings before interest and taxes (EBIT) amounted to MSEK -5,8 (MSEK 8,5). · Earning per share before dilution at SEK -0,09 (SEK 0,13). · Cash flow from operating activities amounted to TSEK -5 929 (TSEK -6 280). · Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9). · Equity ratio was 43 % (87 %).  JANUARY 1[st] – JUNE 30[th ](Previous year in brackets) · Net sales amounted to TSEK 705 (TSEK 302). · Earnings before interest and taxes (EBIT) amounted

Enzymatica announces outcome of new rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. The Board of Directors for Enzymatica (”Enzymatica” or ”Company”) today announces the outcome of the new rights issue with preferential rights for existing shareholders that was published on 19 July 2022 (the “Rights issue”). The new rights issue was fully subscribed, and the Company will receive proceeds amounting to about SEK 74.7 million before issue

Board member Lars Hedbys takes over as acting CEO of RhoVac on 1 September

RhoVac AB ("RhoVac") announces today, August 26[th] 2022, that the board has decided to appoint board member Lars Hedbys as acting CEO of RhoVac, starting from September 1, 2022. As previously announced, Anders Månsson submitted his resignation on 15 July and will take up his new position on 1 September.Gunnar Gårdemyr, chairman of the board: "As Lars has worked on the board of RhoVac since 2015 and has experience from similar assignments, he is well suited to take over the role of acting CEO at Rhovac during the period until RhoVac's future is decided."

Hamlet Pharma Year-end Report July 2021 – June 2022

Opening remarks The fiscal year 2021/2022 of Hamlet Pharma AB has been very successful and important milestones have been reached. The company has consolidated its financial position by raising significant capital, competed successfully for continued funding from the EU Horizon 2020 program, produced drug for clinical trials on a large scale, conducted successful clinical trials, added brain tumor therapy as a new indication for drug development and progressed with the BAMLET drug candidate.Financing and leadership The year started with the successful completion of a funding round

Klaria Interimreport 1 January–30 June 2022 Q2 2022

Klaria Interimreport 1 January–30 June 2022 Q2 2022Summary of the interim report Second quarter of 2022 - Net sales amounted to 0.0 MSEK (0.0 MSEK) - Other income amounted to 3.7 MSEK (0.0 MSEK) - R&D costs for the period amounted to 14.7 MSEK (11.5 MSEK) - Profit after tax amounted to -14.5 MSEK (15.9 MSEK) - Earnings per share for the quarter amounted to -0.24 SEK (0.31 SEK) - Cash flow from operating activities amounted to -15.7 MSEK (13.5 MSEK) - Cash and cash equivalents on the balance sheet date amounted to 7.3 MSEK (39.7 MSEK) - Equity as of June 30

Viking Line – Strong demand partly offset high energy prices

Viking Line Abp              HALF YEAR FINANCIAL REPORT                 26.08.2022, 9.30 AMHalf Year Financial Report for the period January - June 2022 Viking Line – Strong demand partly offset high energy prices   January–June 2022 (compared to January–June 2021)  · Sales amounted to EUR 199.8 M (EUR 71.5 M). · Other operating revenue was EUR 8.3 M (EUR 33.6 M). · Operating income totalled EUR -8.0 M (EUR 4.5 M). · Net financial items were EUR -4.7 M (EUR -2.4 M). · Income before taxes amounted to EUR -12.7 M (EUR 2.2 M). · Income after taxes totalled EUR -9.

Rejlers signs framework agreement with FMV

Rejlers has signed a framework agreement with FMV (the Swedish Defence Materiel Administration) regarding support and expertise in connection to the supply of fixed and mobile power systems. The framework agreement runs for two years with the possibility of an extension for another two years. The Swedish Armed Forces can also call-off on the agreement.FMV procures, develops and delivers materiel and services to the Swedish Armed Forces. Rejlers has extensive experience in supporting FMV with expertise in several areas of technology. The recently signed framework agreement includes expertise

Truecaller for Business launches new and enhanced capabilities for enterprise customers

Truecaller for Business (“TfB”), Truecallers enterprise offering, is now launching several enhanced features like “Video Caller ID”, “Call Me back-function”, “Call Ratings” and “Surveys”. Improvements have also been made to the platform to be able to onboard new clients faster. The new capabilities significantly strengthen Truecallers current enterprise offering.Truecaller for Business, Truecallers enterprise offering, which was launched late 2020 has since inception onboarded a large spectrum of clients across different sectors in India and other focus markets like South Africa, Egypt,

SkartaNYAB Plc acquires Power Forze AB and arranges a directed share issue

SkartaNYAB PlcCOMPANY ANNOUNCEMENT26 August 2022 at 09:30SkartaNYAB Plc acquires Power Forze AB and arranges a directed share issue SkartaNYAB Plc, builder of a clean future, acquires all shares in a Swedish company Power Forze AB. Purchase price for the shares is 38.5 million SEK, of which 8.5 million SEK will be paid as a cash consideration and the remaining by arranging a directed share issue for Power Forze AB’s shareholders. The acquisition has no significant impact on this year’s revenue and result of SkartaNYAB. 4,006,400 new shares in SkartaNYAB Plc will be issued in the

BioStock: Continued positive sales development for Sensidose

Sensidose recently reported an increase in net sales of 21 per cent for the second quarter compared to the same period in 2021. At the same time as the company is growing, they have also made progress during the quarter in the development of the new dosing device, which is expected to drive further growth and profitability in the coming years. The company is now looking forward to the coming months when several pieces of the puzzle are expected to fall into place, according to CEO Jack Spira.Read the full article at biostock.se: https://www.biostock.se/en/2022/08/continued-positive-sales-

Greenfood’s interim report second quarter 2022

The second quarter of the year was characterised by a focus on execution, with increased business traction for Picadeli, Greenfood’s high-tech, sustainable salad concept. Summary of period 1 April – 30 June · Net sales for the period totalled SEK 1,391.6 million (1,117.3) an increase of 24.5%. · Adjusted EBITDA improved significantly with SEK 18.9 million to SEK 69.5 million (50.6) compared with the second quarter 2021. · Operating profit/loss amounted to SEK 4.4 million (7.9) including non-recurring items of SEK -3.8 million (-0.1) and expenses from unestablished businesses

Last day of trading in warrants of series TO 1 is 30 August 2022

Tuesday, 30 August 2022, is the last day of trading in CS MEDICA A/S’s (“CS MEDICA” or the “Company”) warrants of series TO 1 on Spotlight Stock Market. The warrants were issued in connection with the Company’s issue of units that took place in September 2021. Each (1) warrant of series TO 1 entitles the holder to subscribe for one (1) new share in CS MEDICA. Last day to exercise the warrants of series TO 1 and subscribe for shares is 1 September 2022. Note that the banks/nominees need to be notified well in advance before the exercise period ends.Each (1) warrant of series TO 1 entitles

I-Tech AB (publ) Interim report Q2 2022

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the second quarter 2022 Click here on the 26 August 2022 at 10:30 to follow the webcast  Click here to go to I-Tech's Financial Reports Summary of the period ” Record strong sales with increased profitability ” •    Net turnover for the first quarter amounted to 17 654 (12 819) kSEK, corresponding to an increase in turnover of 38% (-21%). Operating profit/loss amounted to 1 469 (-3 192) kSEK. April to June 2022 •

Q2 2022 Interim financial report

FINANCIAL HIGHLIGHTS  · Group revenue of SEK 248.3m (SEK 214.8m). · Gross profit margin 40.7% (38.5%). · EBITDA of SEK 28.5m (SEK 20.3m). · Nonrecurring items of SEK 2.4m related to cost program. · Adjusted EBITDA of SEK 30.9m (SEK 20.3m) · Net operating cash flow SEK 9.7m (SEK 5.1m). · Cost reduction program, Robust 22, finalized with estimated full year effect of appr. SEK 30m. · Freight prices and raw material prices still on high levels. · Delays in deliveries from several suppliers. · Order intake was SEK 294.7m (SEK 266.9m), and order backlog of SEK

Safello Publishes Interim Report for Q2 2022

Stockholm, 26 August 2022 | Today, Safello Group AB (“Safello”) publishes the company’s interim report for the second quarter (1 April-30 June) 2022. The report can be found on safello.com/ir . The quarter was characterized by a high level of activity in regard to executed orders, despite turbulence in the market. “Safello now serves more than 2.5% of Sweden’s population. During the second quarter, we took action to trim the organization and ensure that we operate more

Flexion signs second agreement with tap4fun

LONDON, 26 August 2022 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company has signed an agreement with tap4fun to publish Kiss of War on the alternative app stores. Flexion will distribute the hit game on the ONE store, Amazon and Samsung Galaxy app stores in Q4 2022. Kiss of War is the second game Flexion has launched for tap4fun, having published Kingdom Guard on the alternative app stores in April 2022. This is testament to the increased revenue and audiences tap4fun is seeing thanks to Flexion. “We’re delighted tap4fun has chosen to work with Flexion

The share-based long-term incentive scheme of the key employees of Stockmann plc and its subsidiaries

STOCKMANN plc, Other information disclosed according to the rules of the Exchange 26.8.2022 at 9:00 EET   The Board of Directors of Stockmann plc (the "Company") has decided on the establishment of the share-based long-term incentive scheme targeted to the management and selected key personnel of the Company and its subsidiaries (jointly the “Group”). The incentive scheme consists of a Performance Share Plan (also “PSP”).   The objectives of the Performance Share Plan are to support the implementation of the Company’s strategy, to align the interests of the key personnel with

Glycorex Transplantation AB (GTAB B): Interim report January-June 2022

Accelerating sales growth“Glycorex had a strong second quarter of 2022 with solid double-digit growth. Demand grew as the effects of the COVID-19-pandemic continued to subside which, combined with an effective implementation of the company’s G4G strategy, delivered a very good quarter.”  – Geert Nygaard, CEO Financial information April – June 2022 · Net sales: SEK 11.2 million (8.0) · Operating income: SEK -1.7 million (-2.2) · Net income for the period: SEK -1.7 million (-2.3) · Earnings per share: SEK -0.02 (-0.03) Events in the second quarter · Distributor

Interim report April - June 2022

Quant releases the interim report for April - June 2022.April-June · Net sales for the quarter improved to EUR 43.6 (40.5) million. Organically, net sales increased by 6.0% · During the quarter the contract portfolio value increased by net EUR 12.0 million. One contract was won, four contracts were renewed, and two contracts were lost. Portfolio run rate annualized net sales at the end of the quarter was EUR 188.8 million, compared to EUR 176.8 million at the end of the first quarter of 2022 · Operating loss for the quarter improved compared to prior year and amounted to EUR -0.2

ZINZINO AB (PUBL): INTERIM REPORT SECOND QUARTER 2022

GROWTH DESPITE GREAT UNCERTAINTY IN THE WORLD Revenues during the second quarter of 2022 amounted to SEK 329.5 (322.4) million, which corresponded to 2% (18%) growth compared to the corresponding period last year. The EBITDA result amounted to SEK 20.1 (33.4) million and the EBITDA margin to 6.1% (10.4%). This demonstrated that the company managed to maintain high sales levels combined with profitability despite the influence of external factors. Sharply rising commodity and transportation prices, sales-suppressing shutdowns in the APAC region, and effects of the Russia-Ukraine war made

InDex Pharmaceuticals Holding AB (publ) interim report January – June 2022

PMDA supports InDex’s development plan for cobitolimod in Japan“With great interest from the clinics for our phase III study CONCLUDE and cobitolimod, our successful interactions with the Japanese regulatory authority PMDA, as well as with a strengthened patent portfolio, InDex is strongly equipped for cobitolimod’s path towards market approval”, says Johan Giléus, acting CEO of InDex Pharmaceuticals. Period April – June 2022 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –21.7 (–42.6) million · Result after tax amounted to SEK –21.7 (–42.6)

Karo Pharma Aktiebolag comments on the public offer from Karo Intressenter AB and obtains a fairness opinion

Background On 16 August 2022, Karo Intressenter AB[1] ("Karo Intressenter") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag ("Karo Pharma") to acquire the shares in Karo Pharma not already held by Karo Intressenter (the "Offer") at a price of SEK 60 per share (the "Consideration"). As of the date of this press release, Karo Intressenter holds 236,720,058 shares in Karo Pharma, corresponding to 86.6 per cent of the share capital and votes in Karo Pharma. Hence, Karo Intressenter is the parent company of Karo Pharma. The acceptance period for the Offer

There are no items matching the current filter
There are no more items matching the current filter
Back to top